Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo  by Rivera, Angel A. et al.
www.elsevier.com/locate/yviro
Virology 320 (2004) 121–134Mode of transgene expression after fusion to early or late viral genes of a
conditionally replicating adenovirus via an optimized internal ribosome
entry site in vitro and in vivo
Angel A. Rivera,a Minghui Wang,a Kaori Suzuki,a Taco G. Uil,a,1 Victor Krasnykh,a,2
David T. Curiel,a and Dirk M. Nettelbecka,b,*
aDivision of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center,
University of Alabama at Birmingham, Birmingham, AL, 35294 USA
bDepartment of Dermatology, University Medical Center Erlangen, 91052 Erlangen, GermanyReceived 12 September 2003; returned to author for revision 18 November 2003; accepted 21 November 2003Abstract
The expression of therapeutic genes by oncolytic viruses is a promising strategy to improve viral oncolysis, to augment gene transfer
compared with a nonreplicating adenoviral vector, or to combine virotherapy and gene therapy. Both the mode of transgene expression and
the locale of transgene insertion into the virus genome critically determine the efficacy of this approach. We report here on the properties of
oncolytic adenoviruses which contain the luciferase cDNA fused via an optimized internal ribosome entry site (IRES) to the immediate early
adenoviral gene E1A (AdDE1AIL), the early gene E2B (AdDE2BIL), or the late fiber gene (AdDfiberIL). These viruses showed distinct
kinetics of transgene expression and luciferase activity. Early after infection, luciferase activities were lower for these viruses, especially for
AdDE2BIL, compared with nonreplicating AdTL, which contained the luciferase gene expressed from the strong CMV promoter. However, 6
days after infection, luciferase activities were approximately four (AdDE1AIL) to six (AdDfiberIL) orders of magnitude higher than for
AdTL, reflecting virus replication and efficient transgene expression. Similar results were obtained in vivo after intratumoral injection of
AdDE2BIL, AdDfiberIL, and AdTL. AdDfiberIL and the parental virus, Ad5-D24, resulted in similar cytotoxicity, but AdDE2BIL and
AdDE1AIL were slightly attenuated. Disruption of the expression of neighboring viral genes by insertion of the transgene was minimal for
AdDE2BIL and AdDfiberIL, but substantial for AdDE1AIL. Our observations suggest that insertion of IRES-transgene cassettes into viral
transcription units is an attractive strategy for the development of armed oncolytic adenoviruses with defined kinetics and strength of
transgene expression.
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and McCormick, 1996; Ring, 2002). Thereby, this new
strategy establishes a therapeutic mechanism distinct from
conventional therapies to which advanced cancers are often
resistant. Recent advances in molecular virology and re-
combinant DNA technology have been a major impetus for
this field because they facilitate the engineering of advanced
virotherapeutics.
Adenoviruses possess the critical basic properties that
are required for viral oncolysis (Alemany et al., 2000;
Curiel, 2000; Zhang, 1999). These include a lytic repli-
cation cycle, a highly evolved gene transfer machinery,
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high titers, and a favorable safety profile because of their
low pathogenicity, nonintegrating genome, and genetic
stability. Importantly, the advanced knowledge of adenovi-
rus structure, genome organization, and life cycle allows for
molecular modifications that are required to derive effective
therapeutics. This knowledge has been essential for the
engineering of adenoviruses with tumor-restricted replica-
tion capacity and is also required for the incorporation of
transgenes into the genome of oncolytic adenoviruses.
Conditionally replicative adenoviruses (CRAds) imple-
ment tumor-specific viral replication and cell killing, a
fundamental requirement for the concept of viral oncol-
ysis (Alemany et al., 2000; Curiel, 2000). Most
approaches for the development of CRAds have focused
on the genetic engineering of E1 genes, the first viral
genes expressed after infection of the host cell and key
regulators of adenoviral replication. Within CRAds, E1
genes have been genetically engineered by two means: by
partial or complete gene deletions to ablate functions
which are required for virus replication in normal cells
but dispensable in cancer cells; or by replacement of viral
promoters with tumor-specific promoters. An example for
the former strategy is Ad5-D24, also called dl922-947, a
virus that contains a 24-bp deletion within the conserved
region 2 of the E1A gene (Fueyo et al., 2000; Heise et
al., 2000). The resulting E1A mutant is not able to bind
and inactivate pRb, as required for adenoviral replication
in normal cells. However, pRb binding of E1A in
cancer cells is not necessary, because pRb is inactivated
in the majority of tumors and in proliferating cells per
se, resulting in tumor-selective replication capacity of
Ad5-D24.
Initial clinical studies demonstrated that CRAd injec-
tions were well tolerated (Reid et al., 2002). Moreover,
they validated the concept of adenoviral oncolysis in vivo
by demonstrating tumor-specific viral replication and
tumor cell killing. However, durable responses have been
rare for oncolytic adenoviruses indicating that current
CRAds are not potent enough as a single agent. Interest-
ingly, the clinical observation of synergistic effects of
adenoviral oncolysis and chemotherapy or radiotherapy
resulting in tumor reductions in individual patients
revealed that virotherapy lacks cross-resistance with var-
ious conventional therapies and suggests high potential
for combination therapies.
The co-expression of transgenes by CRAds (reviewed
in Hermiston and Kuhn, 2002) is a new avenue for
improving various aspects of viral oncolysis and is
primarily aimed at the monitoring of CRAd replication
and spread, augmentation of viral release, or combination
therapy. These applications require the incorporation of
different ‘‘genetic payloads’’. For example, transgenes that
encode fluorescent proteins, receptors for radiotracers, or
secretory peptides (Peng et al., 2002; Vassaux and Groot-
Wassink, 2003) have potential for monitoring and trackingof CRAds within the patient. Moreover, apoptosis-induc-
ing genes can be exploited for enhancing release of
adenovirus particles (Sauthoff et al., 2002; van Beuse-
chem et al., 2002). Finally, the incorporation of therapeu-
tic genes can result in a combination therapy mediated by
a single agent, an ‘‘armed CRAd’’. Candidate therapeutic
genes include those encoding prodrug-converting enzymes
for molecular chemotherapy (Akbulut et al., 2003; Bernt
et al., 2002; Freytag et al., 1998; Hawkins and Hermiston,
2001b; Lambright et al., 2001; Lee et al., 2001; Nanda et
al., 2001; Rogulski et al., 2000; Wildner et al., 1999a,
1999b), angiogenesis inhibitors, or cytokines (Bristol et
al., 2003; Hawkins and Hermiston, 2001a, 2001b; Haw-
kins et al., 2001).
These various strategies have different requirements for
quantity and kinetics of transgene expression. They have
to consider the potential interference of transgene expres-
sion or activity of the encoded protein with adenoviral
replication in a given infected cell and likewise, adverse
effects of shutdown of host cell protein synthesis with
quantitative transgene expression. For example, the mon-
itoring of CRAd-infected cells by imaging genes might
require early transgene expression before onset of host
cell shut-off and beginning cell lysis. In contrast, en-
hanced viral release or certain combination therapies
might necessitate late expression of apoptosis-inducing
or cell-killing therapeutic genes to avoid interference with
productive virus replication. In addition, restriction of
transgene expression by CRAds until after replication of
the viral genome prevents transgene function in healthy
cells, where replication of the CRAd genome is blocked.
Thus, a late mode of transgene expression by CRAds is
tumor-specific.
The prime objective of our study was to evaluate a
system for co-expression of transgenes by CRAds that is
based on fusion of a transgene to immediate early, early,
or late viral genes via an internal ribosome entry site
(IRES). This system exploits endogenous viral regulatory
elements such as promoters, splicing signals, leader
sequences, or polyadenylation signals for efficient and
regulated expression of the transgene within a polycis-
tronic message. We generated recombinant oncolytic
adenoviruses derived from Ad5-D24 (Fueyo et al., 2000;
Suzuki et al., 2001) by fusion of the luciferase cDNA to
the viral E1A, E2B, and fiber genes via an improved
IRES. These viruses were analyzed for strength and
kinetics of transgene expression and activity, for the
effect of transgene incorporation on the expression of
surrounding viral genes, and for cytolytic activity in
monolayer cultures. Strength and kinetics of luciferase
activity were also determined after intratumoral injection
into subcutaneous tumors. Our results have important
implications for co-expression strategies in adenoviral
oncolysis and can be combined with the various de-
scribed strategies to restrict Ad replication to tumor
cells.
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Construction of CRAd genomes for early and late
co-expression of transgenes fused to different viral
genes via an optimized IRES sequence
To establish a strategy for exploitation of the adeno-
viral gene expression machinery for transgene expression,
we pursued the strategy depicted in Fig. 1A. The
luciferase reporter gene was fused via an internal ribo-
some entry site (IRES; Martinez-Salas, 1999) to viral
genes E1A, E2B, or fiber of CRAd Ad5-D24 (Fueyo et
al., 2000; Suzuki et al., 2001) in the order viral gene–
IRES–luciferase to generate AdDE1AIL, AdDE2BIL, and
AdDfiberIL, respectively (IRESLuc-CRAds). This strategy
aimed at the efficient transgene expression at immediate
early, early, or late stages of the viral life cycle, respec-
tively. As strong IRES activity is critical for this strategy,
we initially sought to optimize the IRES starting from the
encephalomyocarditis virus (EMCV) IRES which was
previously reported to result in superior transgene expres-
sion of various tested sequences (Harries et al., 2000). In
this regard, positioning of the start ATG codon (Rees et
al., 1996) and the spacing between stop codon of the
upstream gene to the IRES (Attal et al., 1999; Kobayashi
et al., 2001) were reported to influence transgene expres-
sion from the IRES. Three plasmids with the luciferase
gene fused with distinct versions of the EMCV IRES
sequence to the adenoviral E1A gene were generated
(Fig. 1C). The first construct, pSE1ADIRESLuc, contains
the IRES as described previously (Fuerst et al., 1986),
with the start codon used by EMCV mutated and the
start codon of the transgene inserted downstream. In the
second plasmid, pSE1ADIRESLucATG, the start ATG of
the luciferase gene was placed in the original start ATG
position of EMCV. In a third construct, pSE1ADspIRE-
SLucATG, a 54-bp spacer derived from the 3VNTR of the
human CAT gene was placed between E1A gene and
IRES. These constructs and pGL3SV40p, which contains
the strong SV40 promoter driving luciferase expression,
were transiently transfected into A549 cells (Fig. 1C).
The construct with spacer and corrected ATG position
resulted in the strongest luciferase activity, which was
approximately 10-fold higher compared to the construct
without spacer and without original ATG position and
approximately 30% stronger compared with the construct
without spacer, but with original ATG position. Further-
more, this construct resulted in 10-fold higher luciferase
activity than pGL3SV40p, indicating a high level of
transgene expression from E1A-IRES. We thus exploited
the EMCV IRES with the original ATG position and
upstream spacer for designing of the IRESLuc-CRAds.
For this strategy, we had to take the endogenous viral
polyadenylation and promoter sequences into consider-
ation (Fig. 1B). For the generation of AdDE1AIL, a
spacer-IRES-Luc cassette was inserted between the E1Atranslation stop signal and the E1A polyadenylation
sequence, thus 94 bp upstream of the E1B TATA box.
For AdDE2BIL and AdDfiberIL, cloning sites were
generated downstream of the E2B or fiber ORFs, respec-
tively. Furthermore, polyadenylation signals that overlap
with the respective translation stop codons were mutated
(see Materials and methods) to prevent transcription
termination upstream of the inserted IRES. Consequently,
a polyadenylation signal was incorporated downstream of
the inserted spacer-IRES-Luc cassettes for these viruses.
For an overview of the adenoviruses used in this study
see Table 1.
Cytolytic activity of CRAds that contain IRES-transgene
cassettes in different loci
For analysis of the cytolytic activity of IRESLuc-
CRAds, we infected permissive A549 cells with
AdDE1AIL, AdDE2BIL, AdDfiberIL, the parental virus
Ad5-D24 or with nonreplicating AdCMVLuc at multiplic-
ities of infection (MOI) (pfu/cell) 10, 1, 0.1, and 0.01.
Ten days after infection, surviving cells were fixed and
stained with crystal violet (Fig. 2). AdDfiberIL resulted in
similar cytotoxicity as Ad5-D24, whereas AdDE2BIL and
AdDE1AIL were attenuated by less than one order of
magnitude or by approximately one order of magnitude,
respectively (that is less than one order of magnitude or
approximately one order of magnitude higher virus titers
were required to achieve similar cytotoxicity). Thus,
expression of luciferase by CRAds per se did not atten-
uate adenoviral cytotoxicity; however, insertion of the
IRES-transgene cassette at distinct loci, in this case after
the E1A or E2B genes, can reduce cytolytic activity of
CRAds.
Efficacy and kinetics of transgene activity of
IRESLuc-CRAds compared with a first
generation adenoviral vector
Next, we sought to analyze the magnitude and timing
of transgene expression by IRESLuc-CRAds and to com-
pare it to transgene expression directed by the strong
CMV promoter in a first generation, nonreplicative Ad
vector, AdTL (Seki et al., 2002). For this purpose we
infected A549 cells with AdDE1AIL, AdDE2BIL,
AdDfiberIL, or AdTL and determined luciferase activity
6, 10, 14, 18, 22, and 26 h after virus infection (Fig. 3,
left panels). At 6 h postinfection, luciferase activities were
25-fold (AdDfiberIL), 70-fold (AdDE1AIL), or 1443-fold
(AdDE2BIL) lower for the IRESLuc-CRAds relative to
AdTL (Fig. 3A). However, at 26 h postinfection, lucifer-
ase activity of AdDE1AIL was similar to AdTL, and
those of AdDE2BIL and AdDfiberIL were 7-fold or 27-
fold higher, respectively. Thus, transgene expression by
IRESLuc-CRAds was weak early after adenovirus infec-
tion, especially for AdDE2BIL, but increased dramatically
Fig. 1. Strategy for transgene expression from an optimized IRES in CRAds. (A) Locales for insertion of IRES-Luc cassettes into the genome of Ad5-D24.
Deletion of 24 nucleotides of conserved region 2 of E1A (D24) restricts viral replication to tumor cells; the E3 region is deleted (DE3). (B) Individual insertion
sites for IRES-luciferase cassettes into the viral genome. Modifications to the ad genome for insertion of cloning sites and mutation of polyadenylation signals
are shown in red. (C) Analysis of IRES activity. Three plasmids with different E1A-IRESLuc constructs (schematic representation on right) and a plasmid with
SV40 promoter-driven luciferase were transfected into A549 cells. Experiments were performed in triplicates. Mean RLUs and standard deviations (error bars)
are shown on the left.
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luciferase activity at that time point. The increase in
luciferase activity from 6 to 26 h was 47-fold, 3.7 
103-fold, 4.9  105-fold, and 3.1  104-fold for AdTL,
AdDE1AIL, AdDE2BIL, and AdDfiberIL, respectively. Tofurther demonstrate the kinetics of transgene expression of
individual IRESLuc-CRAds with consideration given to
different absolute expression levels, relative luciferase
activities were plotted as fractions of readings at 26
h for each virus individually (Fig. 3B, logarithmic; Fig.
Fig. 2. Cytotoxicity of IRESLuc-CRAds and the parental virus, Ad5-D24.
A549 cells were infected with indicated recombinant adenoviruses at
indicated titers. Adherent cells were stained 10 days after infection with
crystal violet. Dead cells detach and were washed off.
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delayed onset of transgene expression from IRESLuc-
CRAds relative to AdTL. Relative expression from
AdDE1AIL increased earlier during virus infection than
from AdDE2BIL and AdDfiberIL. Surprisingly, luciferase
expression from the fiber fusion construct was higher
relative to the E2B fusion construct at 6 h postinfection
not only in absolute readings (Fig. 3A), but also after
normalization (Fig. 3B). However, relative transgene ex-
pression from AdDE2BIL surpassed relative expression
from AdDfiberIL between 10 and 14 h, whereas the
increase was steeper for AdDfiberIL at later time points.
Overall, these patterns—with the exception of AdDfiberIL
early after infection—resembled the timing of transgene
expression expected from the kinetics of E1A, E2B, and
fiber expression in wild-type adenovirus. However, there
was only a minimal time interval between the onset of
transgene expression from AdDE2BIL and AdDfiberIL
(Fig. 3C).
Next, we evaluated luciferase activity over a more
extended time interval of 6 days after infection of A549
cells with IRESLuc-CRAds and AdTL at 100-fold lower
virus dose (Fig. 3D). On day 1 relative luciferase activities
of all viruses matched those at 26 h of the previous
experiment, however absolute values were near three orders
of magnitude lower, resulting from the lower MOI used for
infection. Luciferase activities for the nonreplicating AdTL
were constant until day 5 and decreased on day 6. In
contrast, luciferase activities for all IRESLuc-CRAds in-
creased continuously over time with the sharpest increase
from day 1 to day 2. On day 6, luciferase activities of
AdDE1AIL, AdDE2BIL, and AdDfiberIL were about four,
five, or six orders of magnitude higher, respectively, than
luciferase activity of AdTL.
Kinetics of mRNA expression from the transgene and from
neighboring viral genes of IRESLuc-CRAds
To analyze the kinetics of expression of luciferase and
viral genes of IRESLuc-CRAds, we quantified the
mRNA expression 5, 10, 15, 20, and 25 h after infectionTable 1
Virus Features
AdCMVLuc Nonreplicating ad, CMV-luciferase
(Reynolds et al., 2001)
AdTL Nonreplicating ad, CMV-luciferase
(Seki et al., 2002)
Ad5-D24 CRAd, E1A CR2 mutant
(Fueyo et al., 2000; Suzuki et al., 2001)
AdDE1AIL Ad5-D24-derived, IRES-Luc fused
downstream to E1A
AdDE2BIL Ad5-D24-derived, IRES-Luc fused
downstream to E2B
AdDfiberIL Ad5-D24-derived, IRES-Luc fused
downstream to fiberof A549 cells by real-time PCR. First, we compared
mRNA copy numbers of luciferase with those of the
fused viral genes E1A, E2B, or fiber after infection with
AdDE1AIL, AdDE2BIL, or AdDfiberIL, respectively. We
determined similar copy numbers for luciferase and E1A,
or luciferase and E2B of AdDE1AIL or AdDE2BIL,
respectively, as expected for messages of a polycistronic
mRNA (Fig. 4A). For AdDfiberIL, copy numbers for
luciferase message were approximately 25% of those of
fiber message over the whole time interval evaluated in
the experiment. This observation might indicate early
transcription termination for a fraction of synthesized
mRNAs.
Next, we assessed whether insertion of heterologous
sequences into the adenoviral genome interferes with
expression of neighboring genes, which is dependent on
the corresponding promoter activity, mRNA stability, and
splicing. Therefore, we compared mRNA expression of
viral genes adjacent to the inserted IRESLuc cassette to
mRNA expression of the same genes in the parental
virus, Ad5-D24. Moreover, we analyzed mRNA copy
numbers of the fiber gene, which, representing late
expression, reflect replication efficiency. For AdDE1AIL,
expression of E1A mRNA was severely attenuated com-
pared with the parental virus, Ad5-D24 (Fig. 4B). This
observation implies that insertion of the IRESLuc cassette,
or of heterologous sequences per se, downstream of the
E1A reading frame reduces transcription of E1A or
stability of E1A mRNA. Also, mRNA copy numbers of
E2B during early infection (until 15 h) and of fiber were
reduced for this virus. For AdDE2BIL, expression of E2B
was slightly decreased at 10–25 h compared with the
parental virus. Protein IX mRNA copy numbers were
similar for AdDE2BIL and Ad5-D24 until 10 h postinfec-
tion, but were lower at later time points. However,
expression of fiber mRNA was almost identical for
AdDE2BIL and Ad5-D24. Compared with the parental
Fig. 3. Kinetics and efficiency of transgene expression by IRESLuc-CRAds versus nonreplicating AdTL: Luciferase assay. A549 cells were infected with
AdDE1AIL, AdDE2BIL, AdDfiberIL, and AdTL at MOI 5 (A–C) or 0.05 (D) and luciferase activities were determined at indicated time points. Experiments
were performed in triplicates. Mean RLUs are shown in A and D. Standard deviations were within the marks. B and C show relative RLUs after normalization
with readings at 26 h for each virus individually. Note the logarithmic scale in diagrams A, B, and D, but linear scale in diagram C.
A.A. Rivera et al. / Virology 320 (2004) 121–134126virus, expression of fiber and E4 messages by AdDfiberIL
was increased early after adenoviral infection but was
similar at later time points. Thus, for AdDE2BIL andAdDfiberIL, expression of neighboring viral genes was
minimally modified without effect on accumulation of
fiber message.
Fig. 4. Kinetics and efficiency of mRNA expression from the transgene and from viral genes of IRESLuc-CRAds and of parental Ad5-D24. A549 cells were
infected with AdDE1AIL, AdDE2BIL, AdDfiberIL, and Ad5-D24. Messenger RNA copy numbers were determined for the indicated genes at 5, 10, 15, 20, and
25 h after infection. (A) Copy numbers of luciferase mRNA and of mRNA of the viral gene to which luciferase was fused via an IRES (as indicated in the
legend) were plotted for the IRESLuc-CRAds (title). (B) Messenger RNA copy numbers of viral genes adjacent to the inserted IRESLuc cassette and of the
fiber gene (as indicated in the title) were plotted for IRESLuc-CRAds versus the parental virus, Ad5-D24 (legend).
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activity
Luciferase activities after infection of A549 with IRE-
SLuc-CRAds correlated with copy numbers of luciferase
mRNA if a delay between mRNA expression and protein
activity was taken into account (Figs. 5 and 3A and 3D).Both luciferase mRNA levels and protein activities initiated
with AdDfiberIL > AdDE1AIL > AdDE2BIL at 5 or 6
h postinfection and eventually were AdDfiberIL >
AdDE2BIL > AdDE1AIL. AdDE2BIL surpassed
AdDE1AIL for luciferase mRNA copy numbers at day 10
postinfection and for luciferase enzyme activity on day 18.
A relatively high luciferase mRNA copy number for
Fig. 6. Luciferase activity in A549 tumors after intratumoral injection of
AdDE2BIL, AdDfiberIL, and AdTL. Viruses were injected into sc A549
xenografts and luciferase activity was determined at indicated days after
infection. Experiments were performed in groups of four mice per virus and
day (3 for AdTL, day 8). Mean RLUs and standard deviations (error bars)
are shown.
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surprisingly high luciferase activity early during virus in-
fection (Figs. 3A and 3B). However, mRNA copy numbers
increased dramatically for AdDE2BIL, but not for
AdDfiberIL from 5 to 10 h postinfection, whereas the
increase was more pronounced for AdDfiberIL after 10 h,
again resembling luciferase activities (Fig. 3B). For AdTL,
mRNA levels correlated with enzyme activity late during
adenovirus replication (compare mRNA copy numbers at 25
h with enzyme activity at day 2). At early time points,
luciferase activity was stronger for AdTL than for IRESLuc-
CRAds until 14 h postinfection, whereas luciferase mRNA
levels were already higher for all IRESLuc-CRAds at 10
h postinfection, reflecting the delay between mRNA expres-
sion and protein activity.
Efficacy and kinetics of luciferase activity of
IRESLuc-CRAds versus a first generation
adenoviral vector in vivo
Next, we evaluated the activity of IRESLuc-CRAds in
vivo. For this purpose, sc A549 xenografts established in
nude mice were injected intratumorally with the IRESLuc-
CRAds AdDE2BIL and AdDfiberIL, which showed the
most promising results in vitro, or with nonreplicating
AdTL. Tumors were harvested at 1, 2, 5, or 8 days postin-
fection and luciferase activity of tumor lysates was deter-
mined (Fig. 6). Overall, the in vivo results resembled our in
vitro observations described above: (i) luciferase activities
strongly increased for both IRESLuc-CRAds, resulting inFig. 5. Luciferase mRNA copy numbers for IRESLuc-CRAds and AdTL.
Luciferase mRNA copy numbers are shown at indicated time points after
infection of A549 cells with AdDE1AIL, AdDE2BIL, AdDfiberIL, and
AdTL.reporter activities more than five orders of magnitude higher
than for AdTL on day 8; (ii) the strongest increase in
luciferase activities for AdDE2BIL and AdDfiberIL was
observed from day 1 to day 2; and (iii) AdDfiberIL resulted
in the highest luciferase activities. In contrast to the in vitro
results, luciferase activities for AdTL decreased from day 1
to day 8. From day 2 to day 8, luciferase activity did not
increase for AdDfiberIL and increased only slightly for
AdDE2BIL.Discussion
Transgene expression by oncolytic viruses is a promising
strategy to improve viral oncolysis, for example, by com-
bination therapy, apoptosis induction for enhanced viral
release, or monitoring of viral spread. Next to the selection
of the candidate transgene, the appropriate mode of trans-
gene expression and a suitable locale of transgene insertion
into the virus genome are pivotal for this approach. Our
study shows that fusion of transgenes via an optimized IRES
to different viral genes of replicating adenoviruses results in
dramatic increases of transgene expression after infection of
tumor cells, both in vitro and in vivo, compared with a
nonreplicating adenovirus which expresses the same trans-
gene from the powerful CMV promoter and enhancer.
Augmentation of transgene activity was up to six orders
of magnitude. For this strategy, we exploited the EMCV
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ATG is critical for efficient transgene expression. Moreover,
insertion of a spacer sequence between the viral gene and
IRES further increased transgene expression. These obser-
vations are in accord with previous reports (Attal et al.,
1999; Kobayashi et al., 2001; Rees et al., 1996).
Of note, various features of the developed IRESLuc-
CRAds depended on the viral gene to which the transgene
was fused. These features were (i) the quantity and timing of
transgene expression, (ii) the influence of transgene inser-
tion on the activity of adjacent viral genes, and (iii) the
oncolytic efficacy. Highest luciferase activity in vitro and in
vivo was achieved by fusion of the luciferase gene to the
viral fiber gene within AdDfiberIL. This virus resulted in
approximately one or two orders of magnitude higher
luciferase activity than AdDE2BIL or AdDE1AIL, respec-
tively. This was expected because the fiber gene is strongly
expressed at late stages of viral infection. Messenger RNA
expression from the fiber and E4 genes, which are adjacent
to the transgene in the genome of AdDfiberIL, varied only
minimally from expression of the same genes by the
parental virus Ad5-D24. Accordingly, cytotoxicity of
AdDfiberIL and Ad5-D24 to tumor cells was identical.
Interestingly, copy numbers of luciferase mRNAwere about
one-fourth of fiber mRNA copy numbers for AdDfiberIL
after infection of A549 cells. This indicates premature
transcription termination, even though the native polyade-
nylation signal of the fiber gene, which overlaps with the
stop codon, was modified. Thus, there might still be
opportunities to further increase transgene expression from
fiber-IRES, for example, by analysis of different polyade-
nylation signal mutants. As expression of the fiber tran-
scription unit is dependent on viral replication (Sauthoff et
al., 2002), transgene expression from fiber-IRES, in contrast
to transgene expression from early viral transcription units,
should be tumor-specific in tumor-targeted CRAds.
For expression of some transgenes by CRAds, for
example, for pro-apoptotic or cytotoxic genes, restriction
of gene expression to late stages of virus replication will be
more important than obtaining high levels of gene expres-
sion. Expression from E1A-IRES is not feasible for this
purpose because of the early onset of transgene expression
as observed for AdDE1AIL (Figs. 3A and 3B). Expression
of the transgene from E2B-IRES might be superior to the
expression from fiber-IRES as suggested by our data.
Surprisingly, luciferase activity was nearly two orders of
magnitude lower for AdDE2BIL compared with AdDfiberIL
early after infection of A549 cells (Fig. 3A). Even after
normalization with luciferase readings at 26 h, relative
luciferase activity was higher for AdDfiberIL than for
AdDE2BIL at 6 h postinfection (Fig. 3B). Correspondingly,
we observed relatively high luciferase and fiber mRNA
copy numbers for AdDfiberIL at 5 h postinfection (Fig.
5). However, luciferase mRNA expression and enzyme
activity increased more for AdDE2BIL than for AdDfiberIL
fiberIL from 5 to 10 h or 6 to 14 h, respectively, but morefor AdDfiberIL at later time points, thus reflecting native
expression patterns in this regard. Copy numbers of both
fiber and luciferase mRNAs were more than one order of
magnitude higher for AdDfiberIL than fiber mRNA copy
numbers for Ad5-D24 at 5 h postinfection. Therefore,
modified viral gene regulation after insertion of heterologus
DNA must for the surprisingly high transgene expression
observed early after virus infection for AdDfiberIL. This
interference with endogenous viral gene regulation might be
due to enhancer activity of the inserted fragment or results
from the modification of mRNA procession or stability.
Such effects might depend on the nucleotide sequence of the
transgene and thus need to be analyzed for each transgene
individually. For AdDE2BIL, the IRES-Luc cassette was
inserted downstream of the E2B reading frame, between the
tail-to-tail-oriented E2B and pIX viral genes. Thus, promot-
er interference, which might be critical for AdDE1AIL (see
below), was not expected. Nevertheless, expression of E2B
and pIX mRNA was reduced after 10 or 15 h, respectively,
postinfection. This indicates that insertion of IRES-Luc
between E2B and pIX interferes with expression of these
genes directly, for example, by affecting mRNA stability, or
indirectly. For AdDE2BIL, in contrast to AdDfiberIL, copy
numbers of luciferase and fused viral messages were nearly
identical, indicating that mutation of the E2B transcription
termination signal in AdDE2BIL was successful and no
premature transcription termination occurred. Cytotoxicity
of AdDE2BIL to A549 cells was somewhat attenuated
relative to Ad5-D24, even though fiber mRNA copy numb-
ers were almost identical from 5 to 25 h for these viruses.
Presumably, reduced viral replication and spread were a
consequence of modified expression of E2B and pIX.
AdDE1AIL showed the strongest interference of the
inserted IRES-Luc cassette with viral gene expression and
cytotoxicity. Expression of E1A mRNA was strongly re-
duced relative to the parental virus Ad5-D24. As the E1A
promoter and enhancer remained unchanged, this is possibly
a result of modified mRNA stability or processing. E1B
mRNA copy numbers were reduced 5–15 h after virus
infection, but not at 20 and 25 h. Modified E1B promoter
activity could be a reason for this observation because the
IRES-Luc cassette was inserted into the E1B promoter
(Parks et al., 1988), as required for fusion to the E1A gene.
Alternatively, reduced read-through transcription from E1A
resulting from the insertion of the heterologous sequence
might be responsible for the decrease in early E1B mRNA
copy numbers. A similar expression pattern for E1B result-
ing from insertion of a transcription termination signal after
the E1A ORF, as previously reported (Maxfield and Spector,
1997), is supportive of this hypothesis. However, we did not
include a transcription termination signal in our inserted
heterologous sequence. These considerations suggest that
insertion of an IRES-transgene cassette in a context of tail-
to-tail-oriented viral genes might be advantageous to con-
serve viral gene expression patterns. Unfortunately, this was
not the case for AdDE2BIL. For AdDE1AIL, luciferase
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For all IRESLuc-CRAds, luciferase activities increased
most dramatically during the first 2 days after virus infec-
tion, after which the increase slowed down considerably
(Fig. 3D). The steep initial increase in luciferase activity
observed early after IRESLuc-CRAd infection is dependent
on promoter activity, mRNA stability, and replication of the
viral genome. However, the increase in luciferase activity
for a given virus at later time points (i.e., after the first round
of replication) depends on viral spread. In addition, trans-
gene expression is less synchronized at later time points.
Still, because IRESLuc-CRAds were not deficient for rep-
lication in A549 cells (Fig. 2) and at least two rounds of
virus replication are expected at the MOI used in the
experiment presented in Fig. 3D, the increase in luciferase
activity between days 2 and 6 might seem surprisingly low.
However, the loss of luciferase-expressing cells by viral cell
lysis in IRESLuc-CRAd-infected cultures (but not in AdTL-
infected cultures) needs to be considered in this context.
In accord with the in vitro results, AdDfiberIL and
AdDE2BIL resulted in approximately six or five orders of
magnitude higher luciferase activity, respectively, after virus
injection into sc A549 tumors when compared with AdTL.
However, in contrast to the in vitro results, luciferase
activities for AdDfiberIL and AdDE2BIL were stable or
increased only minimally from day 2 to day 8. These
observations might indicate that virus spread is less efficient
in vivo than in cell cultures. However, it is also possible that
infected cells might be eliminated faster in vivo than in
vitro, irrespective of virus replication, as suggested by the
early decline of luciferase activity for AdTL in vivo (more
than 10-fold from day 1 to day 8). Thus, the stable luciferase
activities for IRESLuc-CRAds observed in vivo might still
be consistent with virus replication.
IRES sequences have been applied for CRAds for
various purposes, such as expression of multiple viral genes
from one heterologous promoter (Li et al., 2001; Yu et al.,
1999), or co-expression of transgene and viral gene from the
CMV enhancer or promoter (Akbulut et al., 2003; Wildner
et al., 1999b). These reports have also demonstrated func-
tional activity of the IRES in replicating adenoviruses. Our
study extends the analysis of IRES-mediated expression to
transcriptional units not previously investigated. Further-
more, we found that fusion of transgenes via an IRES to the
E1A gene can interfere with expression patterns of neigh-
boring genes. In this regard, our data show that insertion of
IRES-transgene cassettes into the E2B transcription unit
might be advantageous.
Several groups have reported on the combination of
replicating adenoviruses with the expression of apoptosis-
inducing genes, such as p53 (Sauthoff et al., 2002; van
Beusechem et al., 2002), with cytokine genes encoding
TNFa or GM-CSF (Bristol et al., 2003; Hawkins and
Hermiston, 2001a, 2001b; Hawkins et al., 2001), or with
prodrug-activating enzymes (Akbulut et al., 2003; Bernt etal., 2002; Freytag et al., 1998; Hawkins and Hermiston,
2001b; Lambright et al., 2001; Lee et al., 2001; Nanda et
al., 2001; Rogulski et al., 2000; Wildner et al., 1999a,
1999b). The latter studies showed that interference of
drug-mediated cell killing with virus replication and pro-
duction is a critical issue for development of armed
CRAds. In addition to the drug of choice, dosing and
timing of prodrug application influenced the therapeutic
outcome of combination therapy, that is, determined syn-
ergy or interference between virus replication and drug-
dependent cell killing. However, as virus replication in the
tumor is not synchronized over time, timing of enzyme
expression during the adenoviral replication cycle in an
individual infected cell might be advantageous.
The timing of transgene expression by CRAds has been
recently addressed by different strategies. One approach is
to replace an endogenous gene with the transgene of choice.
This strategy has been endeavored with various E3 genes
and has resulted in transgene expression kinetics similar to
those of the replaced gene (Hawkins and Hermiston, 2001a,
2001b; Hawkins et al., 2001; Nanda et al., 2001). Bernt et
al. (2002) have reported on a distinct strategy which results
in replication-dependent transgene expression implemented
by a replication-induced homologous recombination event.
This approach, similar to the insertion of transgenes into late
transcription units, features late transgene expression that is
tumor-specific when adenoviral replication is targeted to
cancer cells. In an approach similar to our strategy, Sauthoff
et al. have reported on expression of p53 from the fiber
transcription unit (Sauthoff et al., 2002). This report shows
that p53 expression mimics expression kinetics of the fiber
gene, which, overall, is in accord with our data for
AdDfiberIL. Furthermore, viral cytotoxicity and release of
virus particles were augmented in a tumor-selective fashion.
Optimization of the IRES sequence, as described herein,
might further improve the strategy of Sauthoff et al. Also, in
those studies, transgene expression was detected by Western
blot. This method might be inadequate to detect variations
of transgene expression early after virus infection, such as
those we detected for AdDfiberIL with the more sensitive
luciferase assay.
We suggest expression of transgenes from distinct viral
transcription units exploiting IRES sequences as a means for
transgene expression with defined kinetics and expression
levels. This strategy does not require the replacement of a
viral gene by the transgene and avoids heterologous pro-
moters, which can show an unfavorable timing of expres-
sion or whose features might not be conserved in the
adenovirus backbone. Various avenues can be pursued to
further improve our strategy. First, given that we deleted the
E3 region to allow for insertion of the luciferase gene,
smaller therapeutic genes would allow for retention of the
E3 region, or of individual E3 genes such as ADP for
improved virus release and spread (Doronin et al., 2000).
However, deletion of ADP in the context of armed CRAds
might also be beneficial as it allows for extended transgene
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sites, further mutations of transcription termination signals,
or viral promoter reconstitution could help to reduce adverse
effects on viral gene expression and replication or to
improve transgene expression. Thirdly, we are currently
analyzing expression of different transgenes by IRES-
CRAds. For example, secreted proteins or apoptosis-induc-
ing proteins might require different expression kinetics than
cytoplasmatic luciferase. Finally, our approach is compati-
ble with any strategy for replication-selectivity, for example,
with promoter-controlled CRAds.Materials and methods
Cell culture
The human tumor cell line A549 (lung adenocarcinoma,
ATCC, Manassas, VA) was cultivated in DMEM (Medi-
atech, Herndon, VA). The human 293 cell line transformed
with Ad5 DNA (purchased from Microbix, Toronto, Can-
ada) was grown in DMEM/F12 (50:50; Mediatech). All
media were supplemented with 10% fetal bovine serum
(HyClone, Logan, UT), 2 mM L-glutamine, 100 IU/ml
penicillin, and 100 Ag/ml streptomycin (all Mediatech).
Cells were grown at 37 jC in a humidified atmosphere of
5% CO2.
Plasmids and recombinant adenoviruses
For a schematic outline of the cloned constructs and
genomes see Fig. 1. Plasmids pGL3IRESLuc, pGL3IRE-
SLucATG, and pGL3spIRESLucATG contained the EMCV
IRES sequence linked upstream to the luciferase gene. For
pGL3IRESLucATG, the IRES sequence was derived by
PCR with oligonucleotides (restriction sites are underlined)
IRES 5V (5V-GATC AGA TCT GCC AAT TCC GCC CCT
CTC CCT) and IRES 3V(5V-GATC CCATGG TAT CAT CGT
GTT TTT CAA AGG AA) and with pIRES-EGFP
(Clontech, Palo Alto, CA) as template. The resulting
fragment was digested with BglII and NcoI and cloned into
the corresponding restriction sites of pGL3 basic (Promega,
Madison, WI). By this strategy, the initiation ATG was
reverted to its original position of the EMC virus. Plasmid
pGL3IRESLuc was generated by inserting the IRES of
plasmid pTM1 (Fuerst et al., 1986) upstream of the
luciferase gene of pGL3 basic without placing the start
ATG to its original position of the EMC virus. Plasmid
pGL3spIRESLucATG is derived from pGL3IRESLucATG
by inserting into the BglII site annealed, 5V-phosphorylated
oligunucleotides CATspacer ts (GAT CTA AGG CAG TTA
TTG GTG CCC TTA AAC GCC TGG TGC TAC GCC
TGA ATA AGT GAT AAA) and CATspacer bs (GATCTT
TAT CAC TTA TTC AGG CGT AGC ACC AGG CGT
TTA AGG GCA CCA ATA ACT GCC TTA) representing a
54-bp spacer derived from the 3V-NTR of the CAT gene withflanking nucleotides for insertion into the BglII site
(underlined). The shuttle plasmids pSE1AD24IRESLuc
and pSE1AD24IRESLucATG were constructed by inserting
a fragment containing the IRES and luciferase gene from
pGL3IRESLuc or from pGL3IRESLucATG, respectively,
into the HpaI site of pShuttleD24 (that contains a deletion of
nucleotides 923–946 corresponding to amino acids
LTCHEAGF of E1A; Suzuki et al., 2002). This restriction
site is located between stop signal and polyadenylation
signal of the E1A gene and 94 nucleotides upstream of the
E1B TATA-box. Plasmid pE1AD24spIRESLucATG was
constructed by inserting a fragment containing spacer,
IRES, and luciferase gene from pGL3spIRESLucATG into
the HpaI site of pShuttleD24. Oligonucleotides E2BMfe5V
(5V-GATC CAA TTG GAT TCT TTG ACC CGG GAA C),
E2BXPrev (5V-AGC AAG CTC GAG GATT CAC GTG
ACA CTT GCT TGATCC AAATCC AAA C), E2BXPfor
(5V-CAC GTG AATC CTC GAG TCA CTTAGG GGT TTT
GCG CGC GCG GTA G), and E2BBstXI3’ (GATC CCA
TCA TTA TGG ACG AAT GCA TGG) were used to
introduce cloning sites downstream of the E2B/Iva2
translational stop site by PCR cloning (inserted restriction
sites for XhoI and PmlI in italics, MfeI and BstXI sites for
cloning underlined) and to simultaneously mutate the E2B
polyadenylation signal in pShuttleD24. Subsequently, the
spacer, IRES, luciferase gene, and polyA sequences from
pGL3spIRESLucATG were inserted into the cloning site of
this plasmid to generate pSD24E2BIL. Plasmid pfiberIL
was generated as follows: restriction sites were incorporated
into the SnaBI site of plasmid pNEB.PK.SnaBI (Wu et al.,
2002) with annealed, 5V-phosphorylated oligonucleotides
Fiberlinker ts (5V-ACT TTT TCA TAC ATT GCC CAA
GAA TGA CTC GAG TAGA ACT AGT AGA) and
Fiberlinker bs (5V-TCT ACT AGT TCTA CTC GAG TCA
TTC TTG GGC AAT GTA TGA AAA AGT), simulta-
neously mutating the fiber polyadenylation signal (inserted
XhoI and SpeI sites in italics). Then, spacer, IRES, luciferase
gene, and polyA sequences from pGL3spIRESLucATG
were inserted into the SpeI (blunt) site. Subsequently, a SpeI
(blunt)/NdeI fragment of pAdEasyI (spanning the E3
deletion; He et al., 1998) was inserted into PacI (blunt)
and NdeI sites of pfiberIL generating pDE3fiberIL. Plasmids
with the genomes of recombinant adenoviruses were
generated by homologous recombination in BJ5183 bacteria
as described (He et al., 1998). For pAdE1ADIL or
pAdDE2BIL, pSE1AD24spIRESLucATG and pSDE2BIL
respectively were recombined with pAdEasyI. For
pAdDfiberIL, pfiberIL was recombined with pVK500 and
subsequently with pShuttleD24. Plasmids were validated by
PCR and restriction digest. Adenovirus particles were
produced by transfection of PacI-digested pAd plasmids
into A549 cells using Lipofectamine (Life Technologies,
Rockville, MD) following the manufacturer’s protocol. E1-
deleted, nonreplicating viruses that express luciferase,
AdTL (Seki et al., 2002), and AdCMVLuc (Reynolds et
al., 2001) were amplified in 293 cells. Ad5-D24 (Fueyo et
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amplified in A549 cells. All viruses were purified by two
rounds of CsCl equilibrium density gradient ultracentrifu-
gation. Verification of viral genomes and exclusion of wild-
type contamination were performed by PCR and restriction
digest. Physical particle concentration (viral particles (vp)/
ml) was determined by OD260 reading and biological
particle concentration (plaque-forming units (pfu)/ml) was
determined by standard plaque assay on 293 cells.
Transfection experiments
For plasmid transfection, 6  104 A549 cells were
seeded per well in a 12-well plate. Cells were transfected
with 0.7 Ag of plasmid per well using Lipofectamine plus
(Life Technologies) according to the manufacturer’s instruc-
tions. Luciferase activity of cell lysates was determined 2
days after transfection using a luciferase assay system
(Promega). Experiments were performed in triplicates; mean
values and standard deviations are shown.
Cytotoxicity assay
For the determination of virus-mediated cytotoxicity,
1.5  104 tumor cells were seeded in 24-well plates and
infected with adenoviruses in 200 Al of growth medium
containing 2% FBS at indicated multiplicities of infection
(MOI = pfu/cell) or mock-infected. The infection medium
was replaced with growth medium the next day. When cell
lysis was observed for Ad5-D24 at the lowest titer 10 days
after virus infection, cells were fixed and stained with 1%
crystal violet in 70% ethanol for 45 min followed by
washing with tap water to remove excess color. The plates
were dried and images were captured with a Kodak DC260
digital camera (Eastman Kodak, Rochester, NY).
Adenovirus infections for luciferase assay
For the determination of transgene expression kinetics, 3
 104 A549 cells were seeded per well in a 24-well plate.
The next day, cells were infected with AdDE1AIL,
AdDE2BIL, AdDfiberIL, or AdTL at indicated MOIs or
mock-infected. Luciferase activity of cell lysates was deter-
mined at indicated time points after virus infection using a
luciferase assay system (Promega). Experiments were per-
formed in triplicates; standard deviations were below 20%
and are not visible at logarithmic scale.
RNA quantification by real-time PCR
For quantification of RNA expression, 1.5  105 A549
cells were seeded per well in a 6-well plate. The next day,
cells were infected with indicated viruses at MOI 20 or
mock-infected. Cells were harvested at indicated time points
after infection and RNA was purified from the cell lysate
with the RNeasy kit including DNase digest (Qiagen,Valencia, CA) following the manufacturer’s instructions.
Quantification of RNA copy numbers was performed by
real-time PCR as follows. TaqMan primers and probes were
designed by the Primer Express 1.0 software and synthe-
sized by Applied Biosystems (Foster City, CA). Oligonu-
cleotide sequences were E1A forward: 5V-AAC CAG TTG
CCG TGA GAG TTG; E1A reverse: 5V-CTC GTT AAG
CAA GTC CTC GAT ACA; E1A probe: 6FAM-CAC AGC
CTG GCG ACG CCC A -TAMRA; E1B forward: 5V-TTT
CTG GCC ATG CAT CTG TG; E1B reverse: 5V-GCG GAC
GGA AGA CAA CAG TAG; E1B probe: 6FAM-AGG
CGA TTC TTG TGT CTC ACA ACC GCT-TAMRA;
pIX forward: 5V-CGC GGG ATT GTG ACT GAC T; pIX
reverse: 5V-TGA ACG GGA AGC TGC ACT G; pIX probe:
6FAM- TGC TTT CCT GAG CCC GCT TGC A-TAMRA;
E2B forward: 5V-GGC ATC TCG ATC CAG CATATC; E2B
reverse: 5V-CCG TGG AAA GAC ATG ACC CT; E2B
probe: 6FAM- TGG ACG AGC ACC GAC TAC TGC
CGT-TAMRA; E4 forward: 5V-GGA GTG CGC CGA GAC
AAC; E4 reverse: 5V-ACT ACG TCC GGC GTT CCAT; E4
probe: 6FAM- TGG CAT GAC ACTACG ACC AAC ACG
ATC T-TAMRA; fiber forward: 5V-TGA TGT TTG ACG
CTA CAG CCA TA; fiber reverse: 5V-GAT TTG TGT TTG
GTG CAT TAG GTG; fiber probe: 6FAM-ACC AAA TTC
AAG CCC ATC TCC TGC ATT AAT G-TAMRA; lucifer-
ase forward: 5V-TGA CCG CCT GAA GTC TCT GA;
luciferase reverse: 5V-TGG AGC AAG ATG GAT TCC
AAT; and luciferase probe: 6FAM-CAG CGG GAG CCA
CCT GAT AGC CT-TAMRA. Human glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) was used as house
keeping gene for internal control. Oligonucleotide sequen-
ces were GAPDH forward: 5V-GGT TTA CAT GTT CCA
ATA TGA TTC CA; GAPDH reverse: 5V-ATG GGA TTT
CCATTG ATG ACA AG; and GAPDH probe: 6FAM-CGT
TCT CAG CCT TGA CGG TGC CAT-TAMRA. With
optimized concentration of primers and probe, the compo-
nents of real-time PCR mixture were designed to result in a
master mix with a final volume of 9 Al per reaction
containing 1 TaqMan EZ RT-PCT Kit (Applied Biosys-
tems), 100 nM forward primer, 100 nM reverse primer, 100
nM probe, and 0.025%BSA. For the assay, a known amount
of template DNA of pTG3602 or pGL3 (108, 106, 104, and
102 copies/Al) was amplified to generate a standard cure for
quantification of the copy numbers of unknown samples.
Known amount of human total RNA (200, 20, 2 and 0.2 ng/
Al) was amplified to generate a standard cure for determi-
nation of the RNA concentration of samples. Total RNA (1
Al) sample was added to 9 Al of PCR mixture in each
reaction capillary. No template control received 1 Al of
water. All capillaries were then sealed and centrifuged using
LC Carousel Centrifuge (Roche Molecular Biochemicals,
Indianapolis, IN) to facilitate mixing. All PCR was carried
out using a LightCycler System (Roche Molecular Bio-
chemicals). Thermal cycling conditions were subjected to 2
min at 50 jC, 30 min at 60 jC, 5 min at 95 jC, and 40
cycles of 20 s at 94 jC and 1 min at 60 jC. Data were
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copy numbers per ng of RNA.
Animal experiments
Female athymic nude mice (Charles River Laboratories,
Inc. Wilmington, MA), 6–8 weeks old, were kept under
pathogen-free conditions. Two million A549 cells were
inoculated sc into the right flank of each mouse. When
tumor nodules reached 5 mm in diameter, a single dose of
5  104 pfu of AdTL, AdDE2BIL, or AdDfiberIL (n = 4 for
each virus and time point, n = 3 for AdTL at day 8) was
administered intratumorally. At indicated days after virus
injection, four mice of each group were sacrificed and
tumors were harvested, snap frozen on dry ice–ethanol,
and stored at 80 jC for determination of luciferase
expression. Tumor specimen were weighed and subsequent-
ly ground to a fine powder using a pestle and mortar cooled
in dry ice–ethanol. Tissue powders were lysed in Cell
Culture Lysis buffer (Promega). After centrifugation, lucif-
erase activity of the supernatant was determined with the
luciferase assay system (Promega). Mean values of RLUs
per tumor and standard deviations are shown. Animal
protocols were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of
Alabama at Birmingham.Acknowledgments
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